(NASDAQ:RARE), NOVATO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted for review the Biologics License Application (BLA) seeking accelerated approval for UX111 (ABO-102) AAV gene therapy as a treatment for patients with Sanfilippo syndrome type A (MPS […]

(LSE:TKO),(TSX:TKO),(NYSE MKT:TGB), VANCOUVER, British Columbia, Feb. 18, 2025 (GLOBE NEWSWIRE) — Taseko Mines Limited (TSX: TKO; NYSE American: TGB; LSE: TKO) (the “Company”) will release its fourth quarter and year end 2024 financial results after market close on Wednesday, February 19, 2025. The Company will host a telephone conference call and live webcast on Thursday,

(NASDAQ:IKT), — Mr. Iwicki Brings Track Record of Operational Excellence and Significant Expertise in PAH and Cardiovascular Diseases — — Amit Munshi Appointed Chair of the Board of Directors — BOSTON, Feb. 18, 2025 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced the appointment of Mark Iwicki as the Company's

(NASDAQ:BIIB),(NASDAQ:STOK), Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights Collaboration broadens Biogen's rare disease pipeline and leverages global expertise commercializing high-value, disease-modifying medicines for rare genetic diseases Pivotal Phase 3 EMPEROR study of zorevunersen on track to initiate in Q2 2025 with

KIRKLAND, Wash., Feb. 18, 2025 (GLOBE NEWSWIRE) — Kestra Medical Technologies Ltd. (“Kestra”), a wearable medical device and digital healthcare company, announced today that Al Ford is joining the company as Chief Commercial Officer (CCO). Mr. Ford will be responsible for advancing sales strategies and leading the Kestra commercial team. “We are pleased to welcome

(NASDAQ:NAUT), SEATTLE, Feb. 18, 2025 (GLOBE NEWSWIRE) — Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating in the TD Cowen 45th Annual Healthcare Conference. Nautilus' management is scheduled to participate in a fireside chat on Monday, March

(NasdaqGM:SPRY), Oral presentation on an efficacy study conducted in Japanese patients comparing anaphylaxis symptoms during oral food challenge with neffy as the initial treatment compared to site historical data on intramuscular auto-injectors, antihistamines and inhalers; patients receiving neffy had lower symptom scores within 10 minutes, supporting neffy as a needle-free option for management of anaphylaxis

(NYSE:CSTM), PARIS, Feb. 18, 2025 (GLOBE NEWSWIRE) — Constellium SE (NYSE: CSTM) today announced a minimum price increase of $0.15 per pound for all flat rolled products shipped in the US, due to recent market dynamics and other economic drivers. Select products may require higher increases. The increase is effective immediately, as contracts allow. About

(NASDAQ:WINT), WARRINGTON, Pa., Feb. 18, 2025 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT) (“Windtree” or the “Company”), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, announces that its board of directors has approved a 1-for-50 reverse stock split of the Company's common stock. The Company's stockholders

(NASDAQ:VTYX), Poster highlights robust, dose-dependent endoscopic response with VTX958 and reductions in key inflammatory markers Full analysis of Phase 2 results, including data from the 52-week treat-through LTE phase, is expected to inform development strategy and partnership opportunities for VTX958 SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) — Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”),